Guidance on parallel EMA/EUnetHTA 21 Joint Scientific Consultation

Table of contents

1 History of Changes ........................................................................................................................................ 6
2 Introduction ............................................................................................................................................... 6
3 Principles .............................................................................................................................................. 7
  3.1 Roles and remits ................................................................................................................................. 7
  3.2 Confidentiality ................................................................................................................................. 7
  3.3 Conflict of interest ............................................................................................................................ 8
  3.4 Status of Parallel EMA/EUnetHTA 21 Joint Scientific Consultation outputs .................................. 8
4 Actors and scope .................................................................................................................................... 8
  4.1 Regulators: actors and scope ............................................................................................................ 8
  4.2 EUnetHTA 21 and HTAbs: actors and scope ................................................................................. 9
  4.3 HTA involvement in Parallel EMA/EUnetHTA 21 Joint Scientific Consultation ......................... 10
    4.3.1 Call for submissions .................................................................................................................. 10
    4.3.2 CSCQ JSC selection criteria, scope and coordination .......................................................... 10
    4.3.3 Parallel EMA/EUnetHTA 21 Joint Scientific Consultation format ........................................ 11
  4.4 Other stakeholders ......................................................................................................................... 11
5 Process ................................................................................................................................................. 12
  5.1 Simultaneous notification .............................................................................................................. 12
  5.2 Presubmission phase ....................................................................................................................... 13
  5.3 Evaluation phase ............................................................................................................................ 14
6 Practical issues ..................................................................................................................................... 22
6.1 Fees.............................................................................................................................................. 22
6.2 Contact points .................................................................................................................................. 22
6.3 Processing of documents .................................................................................................................. 22
6.4 Briefing document for parallel EMA/EUnetHTA 21 Joint Scientific Consultation ....................... 22

7 Other ................................................................................................................................................ 23

7.1 Advice format.................................................................................................................................... 23
7.2 Follow up procedures....................................................................................................................... 23

8 Summary of documents and meeting aims...................................................................................... 23
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AEMPS</td>
<td>Agencia Española de Medicamentos y Productos Sanitarios</td>
</tr>
<tr>
<td>AIFA</td>
<td>Agenzia Italiana del Farmaco, Italy</td>
</tr>
<tr>
<td>ATMPs</td>
<td>Advanced Therapy Medicinal Products</td>
</tr>
<tr>
<td>CAT</td>
<td>Committee for Advanced Therapies</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for Medicinal Products for Human Use</td>
</tr>
<tr>
<td>COMP</td>
<td>Committee for Orphan Medicinal Products</td>
</tr>
<tr>
<td>CSCQ</td>
<td>Committee for Scientific Consistency and Quality</td>
</tr>
<tr>
<td>CSCQ JSC</td>
<td>Joint Scientific Consultation Committee for Scientific Consistency and Quality</td>
</tr>
<tr>
<td>EC</td>
<td>European Commission</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EUnetHTA 21</td>
<td>European Network for Health Technology Assessment 2021</td>
</tr>
<tr>
<td>F2F</td>
<td>Face to Face</td>
</tr>
<tr>
<td>G-BA</td>
<td>Gemeinsamer Bundesausschuss, Germany</td>
</tr>
<tr>
<td>HAS</td>
<td>Haute Autorité de Santé, France</td>
</tr>
<tr>
<td>HCP</td>
<td>Health Care Professional</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>HTAbs</td>
<td>Health Technology Assessment bodies</td>
</tr>
<tr>
<td>INFARMED</td>
<td>National Authority of Medicines and Health Products, I.P., Portugal</td>
</tr>
<tr>
<td>JA</td>
<td>Joint Actions</td>
</tr>
<tr>
<td>JSC</td>
<td>Joint Scientific Consultation</td>
</tr>
<tr>
<td>JSC HOG</td>
<td>Joint Scientific Consultation Hands-On Group</td>
</tr>
<tr>
<td>KCE/KCE-NIHDI</td>
<td>Centre fédéral d'expertise des soins de santé – Belgian Health Care Knowledge Centre (KCE)</td>
</tr>
<tr>
<td>LoI</td>
<td>Letter of Intent</td>
</tr>
<tr>
<td>NCA</td>
<td>National Competent authority</td>
</tr>
<tr>
<td>NCPE</td>
<td>National Centre for Pharmacoeconomics (Ireland)</td>
</tr>
<tr>
<td>NIPN</td>
<td>National Institute of Pharmacy and Nutrition, Hungary</td>
</tr>
<tr>
<td>NOMA</td>
<td>Norwegian Medicines Agency</td>
</tr>
<tr>
<td>PICO</td>
<td>Approach used in evidence-based medicine to define e.g. Population – Intervention – Comparator(s) – Outcome(s)</td>
</tr>
<tr>
<td>PSA</td>
<td>Parallel Scientific Advice</td>
</tr>
</tbody>
</table>
PDCO  Paediatric Committee
PLEG  Post Licensing Evidence Generation
PRAC  Pharmacovigilance Risk Assessment Committee
SAWP  Scientific Advice Working Party
SEED  Shaping European Early Dialogues
SME   Small or Medium Enterprises
TC    Teleconference
1 History of Changes

This guidance replaces the "Guidance for Parallel Consultation" (EMA/410962/2017 Rev.3) as of the date of publication.

Key modifications in this version include:

- the Written-only meeting format has been suspended for the current Open Call within EUnetHTA 21 (all partners will continue to collaborate and discuss future options for different meeting formats besides the face to face (F2F) meeting format);
- Transformation of the early dialogue working party (EDWP) into Committee for Scientific Consistency and Quality for Joint Scientific Consultation (CSCQ JSC), update of the definition and composition of the CSCQ JSC and of the information regarding the EUnetHTA 21 JSC Secretariat;
- Renaming "parallel consultation" to "parallel EMA/EUnetHTA 21 Joint Scientific Consultation"

2 Introduction

As the first step to market access, a new medicine requires a marketing authorisation from a medicines regulatory agency. Following regulatory approval, Health Technology Assessment (HTA), providing evidence-based information and analysis, takes place at the national level in accordance with national practices and legislative frameworks. HTA is then used to inform subsequent decisions on coverage (reimbursement) and price of an authorised drug at the national level.

Interactions between medicines’ developers, Regulators and Health Technology Assessment bodies (HTAbs) or other possible stakeholders to discuss the development plan at an early stage of a medicinal product’s clinical development means that robust evidence can be generated during pre-approval studies to meet the needs of respective decision-makers as efficiently as possible. Thus, a strong interaction between Regulators and HTAbs/other relevant stakeholders is critical to facilitate patients’ access to important new medicines with added value and hence for the overall benefit of public health.

The European Medicines Agency (EMA) is the EU body responsible for coordinating the existing regulatory and scientific resources put at its disposal by EU Member States for the evaluation, supervision and pharmacovigilance of medicinal products, including the provision of Scientific Advice for regulatory purposes.

The European Network for Health Technology Assessment (EUnetHTA) was established to create an effective and sustainable network for HTA across Europe – working together to develop reliable, timely, transparent and transferable information to contribute to HTA in European countries, creating a sustainable system of HTA knowledge sharing, and promoting good practice in HTA methods and processes. In February 2021, a call for tender was launched to foster joint HTA work supporting EU cooperation on HTA beyond May 2021 (when the EU co-funded EUnetHTA Joint Action 3 ended), thus providing relevant input to the new legal framework on HTA. The contract was awarded to the EUnetHTA 21 Consortium in September, 2021. It provides for a maximum of 8 (and not less than 6) Joint Scientific Consultations (JSCs; formerly called Early Dialogues) for medicinal products. The EUnetHTA 21 partners continue to collaborate with EMA on a more efficient procedure while ensuring the best scientific quality and coordination. Our medium-term goal is to establish a regular, legally acceptable solution (respecting confidentiality and conflict of interest rules) to share JSC recommendations with the team producing Joint Clinical Assessment (JCA).

EUnetHTA 21 and EMA platform on evidence generation interactions

This platform comprises enhanced collaboration for Parallel regulatory/HTA Scientific Advice between EMA and EUnetHTA 21 (henceforward referred to as Parallel EMA/EUnetHTA 21 Joint Scientific

---

1 Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.

Guidance for Parallel EMA/EUnetHTA 21 Joint Scientific Consultation (JSC)). Parallel EMA/EUnetHTA 21 JSC provides a single gateway for requests for parallel discussions before the start of pivotal clinical trials on initial evidence generation for Marketing Authorisation Application/Reimbursement, and Post Licensing Evidence Generation (PLEG) involving EMA and EUnetHTA 21 partner HTAbs. Partnership between EMA and EUnetHTA 21 also allows for: streamlined logistics, improved HTA coordination through EUnetHTA 21 JSC Secretariat, greater participation via the involvement of EUnetHTA 21 CSCQ JSC, and maximum gain from the parallel procedure by optimising opportunities for mutual understanding and problem solving between Regulators and HTAs. This facilitates optimal and robust evidence generation for different stakeholders bringing benefits for patient access and public health.

For all submitted requests, the EUnetHTA 21 JSC Secretariat facilitates centralised HTA recruitment, and selection criteria is applied by the CSCQ JSC in order to decide if the request is accepted for a Parallel EMA/EUnetHTA 21 Joint Scientific Consultation. The CSCQ JSC selection criteria and process are fully explained below in section 3.3. Other products which are not selected for a parallel EMA/EUnetHTA 21 JSC could pursue a regular Scientific Advice procedure with EMA and may be eligible for national advice from some HTAbs.

All Parallel Scientific Advices will be conducted through this Parallel Consultation Platform.

3 Principles

3.1 Roles and remits

This guidance highlights ideal timelines and actions for each party undertaking a Parallel EMA/EUnetHTA 21 JSC.

This is a multi-stakeholder procedure with EMA and HTAbs being equal partners. As a multi-stakeholder procedure, collaboration and communication between all stakeholders are important to ensure agreement and clarity on the ownership of different actions, and to deliver on the objectives of the exercise.

Each participating body should adhere to the roles and responsibilities under their respective remit.

3.2 Confidentiality

By submitting a request for a Parallel EMA/EUnetHTA 21 JSC, the Applicant agrees to the exchange of information between EMA and participating EUnetHTA 21 HTAbs.

The Parallel EMA/EUnetHTA 21 JSC process is confidential.

EMA and associated regulatory experts are bound by the EMA code of conduct, and confidentiality agreements, and operate under the EMA policy on access to documents (Policy/0043).

EUnetHTA 21 prioritises confidentiality and each HTAb participant and associated expert, e.g. healthcare professionals and patient representatives, is required to submit a signed EUnetHTA 21 Confidentiality Agreement.

Therefore, commercially confidential information provided to the EMA and EUnetHTA 21 within the context of a Parallel EMA/EUnetHTA 21 JSC is not shared with any party before authorisation outside of the respective EMA and HTA networks in the absence of a signed confidentiality undertaking or the consent of the sponsor.

---

2 Composition of the CSCQ JSC: AIFA (Italy), AEMPS (Spain), G-BA (Germany), HAS (France), INFARMED (Portugal), KCE/KCE-NIHD1 (Belgium), NCPE (Ireland), NIPN (Hungary), NOMA (Norway), TLV (Sweden) and ZIN (Netherlands).
3.3 Conflict of interest

EMA: Conflict of interest of regulatory experts, health care professionals (HCP) and patient representatives is handled in line with Policy 44.

EUnetHTA 21: Conflict of interest of EUnetHTA 21 partner HTAbs, health care professionals (HCP) and patient representatives is handled through the EUnetHTA 21 Declaration of Interest (DOI) form. Further information can be found in the EUnetHTA 21 Procedure Guidance for handling Declaration of Interest (DOI) form. (Links will be updated once new documents are available)

3.4 Status of Parallel EMA/EUnetHTA 21 Joint Scientific Consultation outputs

The advice provided by each stakeholder is not legally binding.

European Medicines’ Regulators take the Committee for Medicinal Products for Human Use (CHMP) Scientific Advice/Protocol Assistance provided into consideration during the Marketing Authorisation Application (MAA). The Applicant needs to fully justify any deviations from the advice given. Please, see the EMA Scientific Advice Guidance document for further details.

Advice provided by EUnetHTA 21 partners is based on the documentation provided by the Applicant. The recommendation reflects the state-of-the-art of medical science and national requirements at the time of advice.

4 Actors and scope

The process described herein is only for Parallel EMA/EUnetHTA 21 JSC jointly involving EMA and EUnetHTA 21. For regulatory-only, please see EMA website and please refer to the EUnetHTA 21 Open Call.

4.1 Regulators: actors and scope

The Scientific Advice Working Party (SAWP) is an EMA standing working party with the remit of providing Scientific Advice and Protocol Assistance to Applicants, advising on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of medicinal products (See "Mandate, objectives and rules of procedure of the Scientific Advice Working Party (SAWP)" (EMEA/CHMP/SAWP/69686/04 Rev 14).

The SAWP Rapporteur is a medicines regulator and a member, or alternate member, of SAWP who is responsible for providing reports further to the Scientific Advice or Protocol Assistance requests, addressing comments from the SAWP, Working Parties, and EMA Committees, drafting the SAWP List of Issues, acting as one of the 2 co-chairs for the F2F meeting, and drafting the final report for further input and consideration by SAWP and EMA Committees.

The EMA Scientific Officer supports the SAWP Rapporteurs with scientific and administrative coordination. This is the principal EMA contact person to be reached, along with the EMA Procedure Assistant, by the Applicant and EUnetHTA 21 for matters related to an individual procedure.

The EMA Scientific advice secretariat informs the EUnetHTA 21 JSC Secretariat who has been appointed as EMA Scientific Officer after receiving the submission via IRIS, while the applicant will be informed automatically by the IRIS system. EMA sends an EMA contact sheet to the EUnetHTA 21 JSC Secretariat including all details for regulator participants (i.e. SAWP Rapporteurs, EMA Scientific Officer, assistant and other contacts, if applicable) as soon as available.

For the EMA, through the Parallel Consultation, the Scientific Advice or Protocol Assistance provided to the Applicant is substantive, is prepared pursuant to Article 57 (1.n) of Regulation (EC) No 726/2004) and is adopted by CHMP having been elaborated through the SAWP.
Applicants may request advice on any medicinal products for use in humans, (as defined in Directive 2001/83 (as amended)), irrespective of the medicinal product’s eligibility for the centralised procedure, and at any stage of the product lifecycle. This may include very early strategic advice, advice on novel development plans, broad advice, plans for pivotal phase III studies, post-authorisation safety and efficacy studies, advice on the development of registries, or risk management planning incorporating risk minimisation measures.

4.2 **EUnetHTA 21 and HTAbs: actors and scope**

The CSCQ JSC is a standing committee composed of 11 national HTAbs as permanent members i.e. AEMPS for Spain, AIFA for Italy, G-BA for Germany, HAS for France, INFARMED for Portugal, KCE/KCE-NIHDI for Belgium, NCPE for Ireland, NIPN for Hungary, NOMA for Norway, TLV for Sweden and ZIN for the Netherlands. The CSCQ JSC is the standing working party of the HTAbs for the performance of the scientific advice and is responsible for the following tasks:

- assess the eligibility of advice requests in view of the Eligibility Criteria, as specified in Section 3.3.2 as well as in the Open Call for Participation, and report to the JSC Secretariat on the eligibility and acceptance of the scientific advice requests;
- participate in the performance of the JSC
- validate all deliverables and give feedback
- Function as a mediation body in cases where a hands-on group cannot reach agreement. The JSC Hands-on Group (JSC HOG) represents all partners involved in a specific JSC.

A EUnetHTA 21 Assessor and Co-Assessor will be assigned for each JSC from among the JSC HOG.

The EUnetHTA 21 Assessor undertakes scientific coordination on behalf of HTAbs. For all procedures, the Assessor facilitates discussion between HTAbs in advance of meetings, interacts with the EMA and acts as a co-chair for the HTAbs. The Assessor is responsible for drafting the EUnetHTA 21 List of Issues, acting as one of the two co-chairs for the F2F meeting with the Applicant, drafting the recommendations for further input and consideration by JSC HOG as well as CSCQ JSC and providing EUnetHTA 21 final consolidated recommendations to the applicant addressing comments from the JSC HOG as well as the CSCQ JSC.

The EUnetHTA 21 Co-Assessor collects and consolidates responses from the JSC HOG and presents consolidated HTAb answers during the F2F Meeting together with the Assessor. The Co-Assessor interacts with the Assessor and EMA on scientific matters. The EUnetHTA 21 Co-Assessor supports the Assessor in the different tasks listed before.

The EUnetHTA 21 JSC Secretariat is responsible for all practical coordination of HTAb participation in a Parallel EMA/EUnetHTA 21 JSC. Together with the EMA Scientific Officer, on the regulatory side, the EUnetHTA 21 JSC Secretariat acts as the sole HTAb contact point for all Parallel EMA/EUnetHTA 21 JSCs. Additionally, the EUnetHTA 21 JSC Secretariat is responsible for insuring the receivability of a request and all project management on the HTAb side. Finally, the EUnetHTA 21 JSC Secretariat is responsible for engaging patients and patients’ representatives and HCPs to provide expert input regarding HTA relevant aspects related to i.a. the condition, treatment and expectations of patients and the proposed development.
4.3 HTA involvement in Parallel EMA/EUnetHTA 21 Joint Scientific Consultation

4.3.1 Call for submissions

The EUnetHTA 21 JSC Secretariat has published an Open Call for applications for Parallel EMA/EUnetHTA 21 JSC. In order to apply for JSC, sponsors/health technologies developers should complete the EUnetHTA 21 JSC application form available on the EUnetHTA website or upon request (EUnetHTA21-JSC@g-ba.de) and submit their application and annexes (if applicable) via Eudralink to the EUnetHTA 21 JSC Secretariat (EUnetHTA21-JSC@g-ba.de). The Applicant’s request for a EUnetHTA 21 JSC should provide sufficient information to substantiate the claimed basis for selection and follow the guidance notes provided with the form. In all cases, the submitted applications must comply with the selection criteria described in the open call for participation. Once the call is closed, the CSCQ JSC members will review the applications. All Applicants will be informed of the CSCQ JSC decision two weeks after termination of the call. Promising products that could not be selected will be considered for a waiting list.

EUnetHTA 21 reserves the right to contact the Applicant in order to discuss their request.

The EUnetHTA 21 JSC Secretariat communicates the outcome of the selection to all Applicants and EMA once the decision is final. For those requests that are selected, information will also be provided regarding the final participating HTAbs to the Applicant and EMA according to the Parallel EMA/EUnetHTA 21 JSC format and to the process outlined in Table 2.

4.3.2 CSCQ JSC selection criteria, scope and coordination

Due to the tender specifications in EUnetHTA 21, the number of products to be selected for the JSC is limited. As the number of applicants is expected to exceed the number of slots, a selection of products will be necessary. With regard to the future HTA regulation, EUnetHTA 21 will apply the same selection criteria as defined in the EU HTA regulation. A prerequisite for a JSC is that the clinical trial (pivotal phase II/ or III) has not yet started.

Promising candidates have to meet all of the following essential criteria to be considered relevant.

- a) unmet medical needs (no treatment or only unsatisfactory treatment available);
- b) first in class;
- c) potential impact on patients, public health, or healthcare systems;
- d) significant cross-border dimension;
- e) major Union-wide added value; or
- f) Union clinical research priorities

Oncology products and/or ATMPs and indications for which there is no established guidance for clinical development (i.e. in absence of recent HTA evaluation in a similar indication) are also given preferred consideration.

As the selection criteria are applied for the first time in this open call, the specification of the selection criteria, their operationalisation and applicability will be further developed in the course of EUnetHTA 21. The generation of consolidated HTA outputs through the CSCQ JSC involves identifying aspects of development programs for which there is a shared position amongst HTAbs and attempting to reach consensus. Where necessary individual positions will be presented in the document annex. The final output is the EUnetHTA 21 Final Written Recommendations, a single written report including: consolidated EUnetHTA 21 Final Recommendations for shared positions, individual HTAb answers to those questions for which consensus was not possible and anonymised transcripts of any patient and/or HCP input obtained through the procedure.
4.3.3 Parallel EMA/EUnetHTA 21 Joint Scientific Consultation format

There is one single procedure for Parallel EMA/EUnetHTA 21 JSCs within the two open calls in EUnetHTA 21; the consultations take place in a F2F meeting format. All Parallel EMA/EUnetHTA 21 JSCs are supported by the EUnetHTA 21 JSC Secretariat, thereby benefiting from HTA scientific and administrative coordination, consolidated HTA comments and List of Issues, a concerted effort to find agreement among the CSCQ JSC regarding specific issues as well as a consolidated document containing EUnetHTA 21’s Final Written Recommendations.

Preliminary exchange on organisational topics will be exchanged with EMA during the Administrative TC.

The entire procedure will be approximately 3,5 months in duration starting from reception of the Draft Briefing Book. The applicant needs to produce written answers to a EUnetHTA 21 List of Issues. The parallel EMA/EUnetHTA 21 JSC with a F2F meeting allows for a direct exchange between the participating HTAbs, EMA and the Applicant. The Applicant will be provided with the Final Written Recommendations from HTAbs only at the end of procedure as indicated on the published timeline. Exchanges between HTAbs and EMA and the high-quality output expected of EUnetHTA 21 are guaranteed for this procedure as well. The full procedure is detailed in Table 2.

4.4 Other stakeholders

From an early stage, the EMA along with HTAbs may consider the need for additional clinical experts in a given procedure and F2F meeting. The inclusion of patient representatives is expected on a routine basis.

EMA

Regulators’ clinical experts are identified through National Competent Authorities (NCA) and SAWP members. An HCP representative may also be invited by the EMA through the EMA HCP Working Party framework, as well as other stakeholders as appropriate.

Individual patient experts are identified through patient organisations under the framework for interaction between the EMA and patients and consumers, and their organisations (EMA/637573/2014).

Where possible, patient representatives are invited to attend all TCs and the F2F meeting; briefing of chairpersons (on the inclusion of a patient representative) and patients (on the aims and nature of the meeting) by EMA Scientific Officer is essential. Any additional time or facilities required by patients should be considered.

EMA exchanges with EUnetHTA 21 JSC Secretariat on the participation of clinical experts and/or patient representatives.

EUnetHTA 21

EUnetHTA 21 is committed to involving experts (patients and HCP) in its work – including JSCs. Hearing directly from patients about the outcomes that matter to them and how their condition impacts their quality of life and hearing directly from HCP about natural disease history and current disease management are areas that are important from an HTA perspective.

EUnetHTA 21 systematically endeavors to involve patients and patients’ representatives in all of its JSCs. In order to best capture this input, EUnetHTA 21 employs three approaches which are outlined in Table 1 below.
Table 1: EUnetHTA21’s three approaches to Expert Involvement

<table>
<thead>
<tr>
<th>Approach</th>
<th>Expert Deliverables</th>
</tr>
</thead>
</table>
| **Approach 1:** Expert interviewed regarding the disease and their experience. | • Minutes of the interview  
• Expert contribution visible in final EUnetHTA 21 recommendations  
• Feedback questionnaire and interview |
| **Approach 2:** Approach 1 + discussion with local HTAb regarding submission file from the Applicant (without applicant). | • Minutes of the interview  
• Expert contribution visible in final EUnetHTA 21 recommendations  
• Share final EUnetHTA 21 recommendations  
• Feedback questionnaire and interview |
| **Approach 3:** Approach 2 + discussion with all participating HTAbs regarding the submission file and participation in the F2F meeting with the applicant. | • Minutes of the interview  
• Expert contribution visible in final EUnetHTA 21 recommendations  
• Share final EUnetHTA 21 recommendations  
• Feedback questionnaire and interview |

The selection of which approach to be used is the responsibility of the EUnetHTA 21 JSC Secretariat, who is also responsible for recruitment. This decision is based on multiple factors including: the identification of a patient and/or healthcare professional corresponding to a specific approach, availability to participate in the procedure, etc. Furthermore, it is possible that multiple approaches may be used in the same JSC.

The EUnetHTA 21 JSC Secretariat exchanges with EMA on the participation of clinical experts and/or patient representatives.

Refinement of the patient participation processes will be carried out within the framework of EUnetHTA 21. Therefore, the process described here may change and the document will be adapted as necessary.

5 Process

5.1 Simultaneous notification

For all Parallel EMA/EUnetHTA 21 JSCs, the Applicants who received a notification of selection by EUnetHTA 21 after the Open Call (see section 3.3) should notify the EMA Scientific Advice secretariat by means of an application submitted via the IRIS platform. The EMA and EUnetHTA 21 Secretariat should simultaneously receive the draft briefing package prior to the deadline published for the intended procedure start date (for submission details, please refer to 4.2 “default without presubmission TC”).

This IRIS submission deadline is approximately 1 month (30 days) before the formal procedure start date (day 0 or SAWP 1) and 3 months before the intended F2F meeting (day 60 or SAWP 3 meeting). For accurate submission deadlines, please refer to the relevant 2022 submission deadlines on the EMA website.

EMA and EUnetHTA 21 JSC Secretariat will then mutually agree the allocation of F2F meeting slots, accommodating any closed HTA meetings, considering the batch of requests for the intended start date. EMA will confirm the date and time of the F2F meeting in writing to EUnetHTA 21 JSC Secretariat and the Applicant by approximately day - 40.
5.2 Presubmission phase

For all Parallel EMA/EUnetHTA 21 JSCs, the presubmission phase starts when the Applicant submits the request to the EMA through IRIS and sends the draft briefing package to the EUnetHTA 21 JSC Secretariat via Eudralink (https://eudralink.ema.europa.eu/).

Default without presubmission TC

By default, the presubmission phase is based on written comments on the draft briefing document.

The draft briefing package should be submitted at least 30 days before the due start date (Day 0 or SAWP1) of the procedure. (See published parallel EMA/EUnetHTA 21 JSC published timetables for a 70 day procedure; SAWP 3 provides the intended F2F meeting date).

In addition to the standard EMA timetables, EMA sets up a timetable in consultation with the EUnetHTA 21 JSC Secretariat for each procedure including closed EMA EUnetHTA 21 interactions following receipt of the submission from the Applicant and confirmation of JSC HOG selection/participating HTAbs from EUnetHTA 21 JSC Secretariat. EMA sends this timetable to all participants. Calendar meeting requests are sent by EMA to the EUnetHTA 21 JSC Secretariat and other regulatory participants shortly after a TC or meeting is confirmed.

The Applicant simultaneously submits the request through IRIS and sends Draft Briefing Document to the EUnetHTA 21 JSC Secretariat in accordance with the agreed timeline. It is important that the timelines are adhered to so that that participants have sufficient time with the draft briefing document in order to provide feedback to the Applicant, and also such that there is sufficient time for the Applicant’s revision before the agreed formal start of the procedure. Initial written comments from the EMA and EUnetHTA 21 JSC Secretariat (collated comments from HTAbs) are provided directly to the Applicant by 15 working days, where necessary for the optimisation of the draft submission prior to the start of the procedure. However, EUnetHTA 21 reserves the right to contact the Applicant in order to request further clarification at any time within the procedure, if needed.

Comments are shared between EMA Scientific Officer and EUnetHTA 21 JSC Secretariat and consider: the scope, wording and clarity of the questions, whether the material provided in the briefing package is sufficient to answer the questions posed, whether all the right questions have been asked or if additional questions should be added, and to consider whether the questions are appropriately addressed to HTAbs, Regulators or both.

Finalising the briefing document

The Applicant submits a revised final briefing document with all annexes and references having addressed the EMA comments and EUnetHTA 21 points of clarification (if any) through IRIS and also sends these to the EUnetHTA 21 JSC Secretariat via Eudralink (https://eudralink.ema.europa.eu/), at least 5 full working days before the start of the procedure. One version should be in “track changes” mode and the other should be “clean”. Both EMA and EUnetHTA 21 JSC Secretariat conduct an administrative check to ensure the briefing package is fit for purpose (i.e. that all annexes and references are present and readable, and that any essential changes have been made to the briefing document).

Following confirmation of validation from EMA, the Applicant submits the final briefing document through IRIS and sends this also to the EUnetHTA 21 JSC Secretariat via Eudralink, before the start of the procedure. The Applicant should ensure that the final briefing document has been received by both parties.

---

3 The submission to EUnetHTA 21 must be done via Eudralink (https://eudralink.ema.europa.eu/) which will allow for the confidential exchange of information between EUnetHTA 21 and the Applicant.
The presubmission phase ends with the circulation of the final briefing document prior to SAWP 1 (Wednesday before start of SAWP; SAWP1 defined according to the published timelines) as in the published Parallel Scientific Advice timelines.

### 5.3 Evaluation phase

**Lists of Issues**

For all Parallel EMA/EUnetHTA 21 JSCs, Lists of Issues facilitate the discussion during the F2F meeting by indicating the focus of Regulators’ and HTAbs’ discussion.

In the regulatory process, the SAWP discusses the first reports (preliminary views) at the SAWP 2 meeting and drafts a Regulators’ List of Issues by approximately day 32 of the procedure.

In the EUnetHTA 21 process, CSCQ JSC members participating in the advice (JSC HOG) discuss draft positions and major issues (following PICO (Population, Intervention, Comparator, Outcome)) pre-listed by the Assessor and Co-Assessor during an e-meeting around day 30 of the procedure.

**Exchange between EMA and HTAbs**

The purpose of the pre-F2F TCs is to exchange and understand respective (preliminary) positions of the different Regulator and HTAb participants on the major aspects of trial designs such as population, comparator or endpoints should be identified. Potential solutions that could facilitate one trial, or at least one development plan, could be discussed in advance of the F2F meeting. The Regulator’s chairperson for the F2F meeting should be agreed in the pre-F2F TC.

The EMA arranges a first closed preparatory TC between EMA and EUnetHTA 21 (JSC Secretariat, Assessor and Co-Assessor), to take place around day 35 of the procedure, focusing on draft recommendations and the issues identified by Regulators and HTAbs. Final versions of List of Issues are sent to the Applicant by the EMA and EUnetHTA 21 JSC Secretariat respectively after the TC. They are also exchanged between EMA and EUnetHTA 21 JSC Secretariat.

**Preparation for F2F meeting**

The Applicant can contact the EMA Scientific Officer and/or EUnetHTA 21 JSC Secretariat regarding the format of the F2F meeting. This is to ensure that the meeting fulfils the needs of involved stakeholders. The Applicant should send any written responses to the EUnetHTA 21 List of Issues 12 working days before the F2F meeting directly to EUnetHTA 21 JSC Secretariat. For EMAs List of Issues, the applicants’ written response is expected 5 working days before the start of the F2F meeting week (SAWP3 meeting week, according to the published timelines). There should be no major changes to the development plan compared to the final briefing document, unless the process in topic “Amended development plans” has been followed.

The Applicant should submit the final presentation and list of participants directly to all EMA contacts and to EUnetHTA 21 JSC Secretariat, 2 working days before the end of the week preceding the F2F meeting week (SAWP3 meeting week, according to the published timelines). Any changes to the presentation after this date will not be accepted. The presentation can include a very brief introduction, rationale and status of the program. An upper limit of 5 slides for this introduction is recommended to maximise the time available for the questions and discussion. Once shared with the meeting participants, according to the agreed timelines, the presentation should not be amended by the Applicant. There should be no major changes to the development plan compared to the final briefing document, unless the process in topic “Amended development plans” has been followed.

The EUnetHTA 21 JSC secretariat is asked to send their final list of attendees to the EMA also in advance of the meeting (1 week before the F2F). Applicants may have up to 12 representatives which can be increased to 14 in case of applicants between collaborating companies. The EMA circulates a preliminary
list of all participants 2 days in advance of the F2F meeting. The meeting is hosted at the EMA premises (in person or virtually via TC).

**Amended development plans triggered by the lists of issues or external factors/written response to List of Issues**

Amended development plans triggered by the Lists of Issues or external factors can be accommodated to some extent during the evaluation phase. However, to facilitate sufficient time for review of the amended development plan, it is stressed that the Applicant should advise all parties of their intention to submit an amended development plan as early as possible, before the F2F meeting. The amended plan must be received by all parties together with a clear comparative table of changes in the plans and justification for the changes.

For EUnetHTA 21, the written response to List of Issues and, if applicable, necessary information regarding the amended development plan must be received at the latest by 12 working days before the F2F meeting. Any substantial changes to the development plan submitted past this date cannot be addressed within the F2F meeting or reflected in the minutes.

For EMAs List of Issues, the applicants’ written response and, if applicable, necessary information regarding the amended development plan is expected 5 working days before the start of the F2F meeting week (SAWP3 meeting week, according to the published timelines).

**F2F discussion meeting**

The aims of the F2F meeting are:

- To discuss issues of concern or disagreement from EMA and/or HTAbs with the Applicant’s proposal regarding major aspects of trial designs
- To get a mutual understanding of each body’s constraints as it has to be acknowledged that regulators and HTAbs are operating within distinct remits (benefit/risk evaluation vs added value or cost-effectiveness’ evaluation). Possible resulting divergences between HTAbs and regulators positions on major aspects of the trial design will be discussed.
- To share and discuss preliminary positions on major aspects of trial designs from EUnetHTA 21 with all participants
- To discuss potential solutions that could facilitate one trial design or at least one development plan

The F2F meeting has 2 co-chairs: one from EMA and one from the HTAbs. The meeting duration will depend on the range of issues to be discussed, the maximum length of the meeting is 3 hours.

Before the Applicant enters the room, the Regulators and the HTAbs have the opportunity to have a closed session in order to interact on any possible changes of position after the Applicant’s responses and presentation. This pre-meeting could be extended if necessary (e.g. late changes to the development plan). EUnetHTA 21 will share the outcome of the closed HTAb meeting (referred to as closed JSC HOG pre-F2F meeting) with EMA with a summary of common positions on major issues and related expert input.

The meeting with the Applicant is interactive, focusing on the issues raised by the Regulator and the HTAbs in the Lists of Issues. It is usual to pause after each question/issue for discussion. During the F2F meeting, the views of each stakeholder should be clearly represented on each issue. Time should be allowed for summing up at the end of the meeting.

Following the F2F meeting, a closed debriefing between HTAbs and Regulators should be held. This is dedicated to the recap, identification and discussion of any outstanding divergences, where such divergences mean that a single development plan/trial could not be carried out. There might be situations
in which the divergences cannot be resolved due to differences in the Regulators’ and HTAbs’ assessment questions and remit.

The Applicant is expected to provide detailed minutes of the F2F meeting, within 5 working days directly to EMA and the EUnetHTA 21 JSC Secretariat. The minutes should reflect the views for each participating stakeholder in the F2F meeting discussion. Areas of agreement and divergence of opinion between Regulators and HTAbs should be summarised by the Applicant. Minutes are regarded as an Applicant’s record of the meeting and will not, in general, be endorsed by the participating bodies.
<table>
<thead>
<tr>
<th>Day</th>
<th>Applicant</th>
<th>EMA</th>
<th>EUnetHTA 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>D - 30</td>
<td>Applicant submits the draft briefing document with annexes and references simultaneously to the EUnetHTA 21 JSC Secretariat via Eudralink⁴ and to the EMA via IRIS.</td>
<td>IRIS automatically confirms receipt of the draft briefing document, annexes and references. Communication of EMA contact point (EMA Scientific Officer) to Applicant and EUnetHTA 21 JSC Secretariat. IRIS submission triggers appointment of 2 SAWP Rapporteurs and, where appropriate, a SAWP Rapporteur for questions relating to significant benefit (only applicable for protocol assistance) by the SAWP.</td>
<td>EUnetHTA 21 JSC Secretariat confirms receipt to the applicant and informs JSC HOG + CSCQ. Appointment of Scientific coordinator and rapporteur, information shared with EMA. EUnetHTA 21 JSC Secretariat communicates the draft briefing document, annexes and references to JSC HOG + CSCQ. Assessor and Co-Assessor can request any necessary clarifications to the applicant and copied to EMA Scientific Advice (SA) secretariat at any time.</td>
</tr>
<tr>
<td>D - 15</td>
<td>Feedback on draft</td>
<td></td>
<td>External experts are identified, and information shared with EMA.</td>
</tr>
<tr>
<td>D - 10</td>
<td>Administrative TC between EMA and EUnetHTA 21 JSC Secretariat.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Outline of actions for Applicant, EMA and EUnetHTA 21 in Parallel EMA/EUnetHTA 21 JSCs

### Validation of briefing package

<table>
<thead>
<tr>
<th>Day</th>
<th>Applicant</th>
<th>EMA</th>
<th>EUnetHTA 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>D - 5</td>
<td>Submission</td>
<td>Validation of Final Briefing Document</td>
<td>Validation of final briefing document:</td>
</tr>
<tr>
<td></td>
<td>The <strong>Applicant</strong> submits the briefing package together with annexes and references in response to the request(s) for clarification to the EMA via IRIS and to EUnetHTA 21 via Eudralink. One version of briefing document should be in “track changes” mode and the other should be “clean”.</td>
<td>Notification of positive validation of the final briefing document by EMA Scientific Advice secretariat to the Applicant via IRIS and information of the EUnetHTA 21 JSC Secretariat thereof at D -2 together with final instructions.</td>
<td><strong>EUnetHTA 21 JSC Secretariat</strong> confirms validation to the Applicant and EMA.</td>
</tr>
</tbody>
</table>

### Submission of final briefing package

<table>
<thead>
<tr>
<th>Day</th>
<th>Applicant</th>
<th>Validation of final briefing document:</th>
</tr>
</thead>
<tbody>
<tr>
<td>D - 2</td>
<td>The <strong>Applicant</strong> submits final briefing package including annexes and references to the EMA via IRIS <strong>and to the EUnetHTA 21 JSC Secretariat</strong> via Eudralink.</td>
<td><strong>EUnetHTA 21 JSC Secretariat</strong> shares the final briefing document with <strong>JSC HOG + CSCQ</strong>.</td>
</tr>
</tbody>
</table>

### Evaluation Phase

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Discussion of the first reports during SAWP meeting focusing on controversial issues followed by production of a draft List of Issues, which outlines the topics of Regulators’ interest to be addressed by the Applicant in the F2F meeting.</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Preliminary discussion (e-meeting) on JSC HOGs’ position on main topics (PICO) of the development proposed and exchanges on related issues. Followed by production of a EUnetHTA 21 List of Issues draft, which outlines the topics of</strong></td>
</tr>
<tr>
<td>Day</td>
<td>Applicant</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
|      |           |     | **HTAbs interest to be addressed by the**
<p>|      |           |     | <strong>Applicant in the F2F meeting.</strong> |
|      |           |     | ✓ <strong>JSC HOG</strong> starts to discuss the draft written positions. |
| ~D + 32 | <strong>EUnetHTA 21 JSC Secretariat</strong> and EMA exchange their respective draft Lists of Issues. |
|      | EMA and SAWP Rapporteurs take part in a closed e-meeting (preF2F TC) with EUnetHTA 21 JSC Secretariat, EUnetHTA 21 Assessor and Co-Assessor. |
|      | ✓ <strong>Finalisation of List of Issues</strong> |
|      | ✓ <strong>After the pre-F2F TC EMA sends SAWP List of Issues to the Applicant and EUnetHTA 21 JSC Secretariat.</strong> |
|      | ✓ <strong>Finalisation of List of Issues</strong> |
|      | ✓ <strong>After the pre-F2F TC EUnetHTA 21 JSC Secretariat sends the List of Issues to the Applicant and the EMA.</strong> |
| D + 45 | ✓ <strong>Applicant</strong> sends their written responses (if applicable) to the List of Issues raised by EunetHTA 21 via Eudralink to the <strong>EUnetHTA 21 JSC Secretariat</strong> (if applicable: notification of amended development plan with changes and justifications). |
|      | ✓ <strong>EUnetHTA 21 JSC Secretariat</strong> distributes the Applicant’s written response and any notification of amended development plan with changes and justification (if applicable) to <strong>JSC HOG.</strong> |
| ~D + 55 | ✓ <strong>Applicant</strong> sends their written responses (if applicable) to the List of |
|</p>
<table>
<thead>
<tr>
<th>Day</th>
<th>Applicant</th>
<th>EMA</th>
<th>EUnetHTA 21</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>~D + 55</td>
<td>▶ Applicant submits power point presentation to <strong>EMA</strong> via <strong>IRIS</strong> and <strong>EUnetHTA 21 JSC Secretariat via Eudralink</strong>, at least 2 full working days before the week preceding the F2F meeting week (SAWP3 meeting week), addressing the Lists of Issues for both HTAbs and Regulators. The Applicant should group related issues together. Further changes after this date will not be accepted.</td>
<td></td>
<td>▶ Closed JSC HOG pre-F2F e-meeting: Review comments on draft written recommendations and prepare F2F discussion on preliminary EUnetHTA 21 consolidated recommendation on main topics (PICO).</td>
</tr>
<tr>
<td>D + 60</td>
<td>▶ Applicants submits list of participants.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F2F Meeting</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tripartite session: F2F meeting between JSC HOG and EMA with the Applicant.** The meeting takes place at the EMA premises and will normally have 2 co-chairs: one from the Regulators and one from the HTAbs (the **JSC HOG Assessor**). The meeting duration will depend on the range of issues to be discussed (maximum 3 h), with 15 minutes closed pre, and 15 minutes closed post F2F (EMA and EUnetHTA 21). Pre-meeting could be extended if necessary (e.g. late changes to the development plan). Pre-meeting with EMA and EUnetHTA 21 sharing draft positions, expert’s feedback received by the two parties and discussing last minute changes.
The **Applicant** addresses key issues that were identified by **EUnetHTA 21 JSC** and **EMA**. An interactive discussion follows on the key issue.

<table>
<thead>
<tr>
<th>Day</th>
<th>Applicant</th>
<th>EMA</th>
<th>EUnetHTA 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>D + 70</td>
<td></td>
<td>➢ The Regulators’ <strong>Final Advice Letter</strong> is adopted by the CHMP (and by the COMP in case of questions on significant benefit for Protocol Assistance), made available to Applicant via IRIS and sent to the <strong>EUnetHTA 21 JSC Secretariat</strong>.</td>
<td>➢ Finalisation of EUnetHTA 21 Final Written Recommendations between D +61 and D +82.</td>
</tr>
<tr>
<td>D + 82</td>
<td></td>
<td></td>
<td>➢ <strong>EUnetHTA 21</strong> Final Written Recommendations sent to Applicant and EMA.</td>
</tr>
<tr>
<td>D + 85</td>
<td><strong>Applicant</strong> completes and returns feedback questionnaire to the <strong>EUnetHTA 21 JSC Secretariat</strong>.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
6 Practical issues

6.1 Fees

The EMA charges fees for this procedure, which are the same as for standard Scientific Advice/Protocol Assistance including the application of any fee incentives. For more information see Fees payable to the European Medicines Agency.

The participation of HTA bodies in the JSCs offering consolidated HTA outputs elaborated through CSCQ JSC in the frame of the EUnetHTA 21 Consortium Action is covered by EUnetHTA 21 budget.

6.2 Contact points

It is preferable to have a principal point of contact (with back-up) for each stakeholder. The points of contact should be confirmed for each procedure.

The EUnetHTA 21 JSC Secretariat is the point of EUnetHTA 21 contact in relation to all HTA aspects, unless otherwise indicated.

The EMA Scientific Officer is the principal EMA contact person to be contacted, along with the EMA Procedure Assistant, by the Applicant and EUnetHTA 21 for queries related to an individual procedure. Applicants’ are instructed to submit their documents and any questions through IRIS and in relation to the relevant submission.

The Applicant should keep the EUnetHTA 21 JSC Secretariat up to date with changes in contact details. Changes in contacts should also be implemented by applicants directly in IRIS.

6.3 Processing of documents

The Parallel EMA/EUnetHTA 21 JSC uses Eudralink for exchanging documents between the applicant and the EUnetHTA 21 JSC Secretariat. Document exchange between the Applicant and EMA takes place through the IRIS platform.

The Applicant is responsible for sending the briefing documents directly to the EUnetHTA 21 JSC Secretariat and EMA. The Applicant must ensure that receipt of documents has been acknowledged by all the participants.

Document version control, numbering, and adherence to timelines are essential to ensure all parties have the appropriate document at the correct time. It is strongly advised to avoid making significant changes to the documentation/clinical development close to the F2F meeting except where this has been discussed and agreed with participants. This is in order to guarantee an appropriate time for the revision and the evaluation by Regulators and HTAbs.

The Applicant provides consent to document exchange between EMA and EUnetHTA 21 in the Application Form.

6.4 Briefing document for parallel EMA/EUnetHTA 21 Joint Scientific Consultation

A common briefing document is used; each question can be addressed to the Regulators or the HTAbs alone, or to both. Quality and nonclinical questions are possible during a Parallel EMA/EUnetHTA 21 JSC
procedure and posed to regulators only. In the same manner questions related to health economics are possible and should be directed to HTAb's only. The labelling of questions is a guide but does not prevent interested bodies answering questions deemed also relevant and of interest. In any case, EUnetHTA 21 recommendations will be organised using the PICO approach. Applicants are encouraged to submit detailed information concerning the choice of patient reported outcomes and any post-launch evidence generation plans. Use of the associated briefing document template is required (See published template for Parallel Consultation). (Link will be updated once new documents are available)

7 Other

7.1 Advice format

The EMA will provide via IRIS the CHMP final Scientific Advice/Protocol Assistance letter to the Applicant in accordance with the published timelines (i.e. the subsequent CHMP meeting). (Link will be updated once new documents are available)

The EUnetHTA 21 JSC Secretariat sends out validated final written recommendations at day +82. Final outcome letters are exchanged between EMA and EUnetHTA 21 JSC Secretariat.

7.2 Follow up procedures

A follow-up procedure to an earlier Parallel Consultation procedure for the same indication is possible. There is no time window during which this has to be completed. The briefing document should contain a clear table of the changes compared to the previously reviewed development plan with justifications.

However, for conflict of interest reasons, HTAb's avoid collaborative development with Applicant through iterative process.

8 Summary of documents and meeting aims

**Table 4.** Description of documents

<table>
<thead>
<tr>
<th>Documents</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open Call Application Form</td>
<td>Application form for the formal expression of interest by an applicant (available for submission by the Application during Open Call periods on the EUnetHTA website or upon request via <a href="mailto:EUnetHTA21-JSC@g-ba.de">EUnetHTA21-JSC@g-ba.de</a>)</td>
</tr>
<tr>
<td>Draft briefing document</td>
<td>Draft briefing document comprising the questions and Applicant’s positions, as well all the relevant information, annexes and references, important to assess such questions.</td>
</tr>
<tr>
<td>Final briefing document</td>
<td>Finalised version of the draft briefing document addressing regulators’ comments and HTAb’s points of clarification, including all annexes and references - with adaptations in text and reference list highlighted.</td>
</tr>
<tr>
<td>SAWP List Of Issues</td>
<td>Documents outlining the concerns or disagreements with the Applicant’s proposal. Further justifications, clarification or changes to the Applicant’s proposals are requested.</td>
</tr>
<tr>
<td>EUnetHTA 21 List Of Issues</td>
<td></td>
</tr>
<tr>
<td>Final CHMP Scientific Advice/</td>
<td></td>
</tr>
<tr>
<td>Documents</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Protocol Assistance letter</td>
<td></td>
</tr>
<tr>
<td>EUnetHTA 21 Final Written</td>
<td></td>
</tr>
<tr>
<td>Recommendations</td>
<td></td>
</tr>
</tbody>
</table>